{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:39:59Z","timestamp":1778938799911,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VENI-016-106-117"],"award-info":[{"award-number":["VENI-016-106-117"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2007T046, 2019T064"],"award-info":[{"award-number":["2007T046, 2019T064"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91111.006"],"award-info":[{"award-number":["91111.006"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pflugers Arch - Eur J Physiol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Erythropoietin (EPO) is a haematopoietic hormone that regulates erythropoiesis, but the EPO-receptor (EpoR) is also expressed in non-haematopoietic tissues. Stimulation of the EpoR in cardiac and skeletal muscle provides protection from various forms of pathological stress, but its relevance for normal muscle physiology remains unclear. We aimed to determine the contribution of the tissue-specific EpoR to exercise-induced remodelling of cardiac and skeletal muscle. Baseline phenotyping was performed on left ventricle and m. gastrocnemius of mice that only express the EpoR in haematopoietic tissues (EpoR-tKO). Subsequently, mice were caged in the presence or absence of a running wheel for 4\u00a0weeks and exercise performance, cardiac function and histological and molecular markers for physiological adaptation were assessed. While gross morphology of both muscles was normal in EpoR-tKO mice, mitochondrial content in skeletal muscle was decreased by 50%, associated with similar reductions in mitochondrial biogenesis, while mitophagy was unaltered. When subjected to exercise, EpoR-tKO mice ran slower and covered less distance than wild-type (WT) mice (5.5\u2009\u00b1\u20090.6 vs. 8.0\u2009\u00b1\u20090.4\u00a0km\/day, p\u2009&lt;\u20090.01). The impaired exercise performance was paralleled by reductions in myocyte growth and angiogenesis in both muscle types. Our findings indicate that the endogenous EPO-EpoR system controls mitochondrial biogenesis in skeletal muscle. The reductions in mitochondrial content were associated with reduced exercise capacity in response to voluntary exercise, supporting a critical role for the extra-haematopoietic EpoR in exercise performance.<\/jats:p>","DOI":"10.1007\/s00424-021-02577-4","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T20:02:15Z","timestamp":1623960135000},"page":"1301-1313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise"],"prefix":"10.1007","volume":"473","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-5698","authenticated-orcid":false,"given":"Kirsten T.","family":"Nijholt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M. G.","family":"Meems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem P. T.","family":"Ruifrok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.","family":"Maass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salva R.","family":"Yurista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario G.","family":"Pavez-Giani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belend","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk H. G.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiek H.","family":"van Gilst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman H. W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-7019","authenticated-orcid":false,"given":"B. Daan","family":"Westenbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"2577_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1152\/jappl.2001.90.5.1900","volume":"90","author":"DL Allen","year":"2001","unstructured":"Allen DL, Harrison BC, Maass A, Bell ML, Byrnes WC, Leinwand LA (2001) Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol 90:1900\u20131908. https:\/\/doi.org\/10.1152\/jappl.2001.90.5.1900","journal-title":"J Appl Physiol"},{"key":"2577_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00421-015-3322-6","volume":"116","author":"S Annaheim","year":"2016","unstructured":"Annaheim S, Jacob M, Krafft A, Breymann C, Rehm M, Boutellier U (2016) RhEPO improves time to exhaustion by non-hematopoietic factors in humans. Eur J Appl Physiol 116:623\u2013633. https:\/\/doi.org\/10.1007\/s00421-015-3322-6","journal-title":"Eur J Appl Physiol"},{"key":"2577_CR3","doi-asserted-by":"publisher","first-page":"100632","DOI":"10.1016\/j.blre.2019.100632","volume":"39","author":"TS Atkinson","year":"2020","unstructured":"Atkinson TS, Kahn MJ (2020) Blood doping: then and now. A narrative review of the history, science and efficacy of blood doping in elite sport. Blood Rev 39:100632","journal-title":"Blood Rev."},{"key":"2577_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/imj.12629","volume":"45","author":"V Birzniece","year":"2015","unstructured":"Birzniece V (2015) Doping in sport: effects, harm and misconceptions. Intern Med J 45:239\u2013248. https:\/\/doi.org\/10.1111\/imj.12629","journal-title":"Intern Med J"},{"key":"2577_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0008-6363(02)00704-6","volume":"57","author":"RA de Boer","year":"2003","unstructured":"de Boer RA, Pinto YM, Suurmeijer AJH, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH, van Veldhuisen DJ (2003) Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 57:434\u2013442","journal-title":"Cardiovasc Res"},{"key":"2577_CR6","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1073\/pnas.0630444100","volume":"100","author":"L Calvillo","year":"2003","unstructured":"Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802\u20134806. https:\/\/doi.org\/10.1073\/pnas.0630444100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2577_CR7","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.109.214353","volume":"106","author":"MS Carraway","year":"2010","unstructured":"Carraway MS, Suliman HB, Jones WS, Chen C-W, Babiker A, Piantadosi CA (2010) Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. Circ Res 106:1722\u20131730. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.214353","journal-title":"Circ Res"},{"key":"2577_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-29865-x","volume":"8","author":"KS Cheung Tung Shing","year":"2018","unstructured":"Cheung Tung Shing KS, Broughton SE, Nero TL, Gillinder K, Ilsley MD, Ramshaw H, Lopez AF, Griffin MDW, Parker MW, Perkins AC, Dhagat U (2018) EPO does not promote interaction between the erythropoietin and beta-common receptors. Sci Rep 8:1\u201316. https:\/\/doi.org\/10.1038\/s41598-018-29865-x","journal-title":"Sci Rep"},{"key":"2577_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1751-7133.2009.00135.x","volume":"16","author":"RS Cohen","year":"2009","unstructured":"Cohen RS, Karlin P, Yushak M, Mancini D, Maurer MS (2009) The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Hear Fail 16:96\u2013103. https:\/\/doi.org\/10.1111\/j.1751-7133.2009.00135.x","journal-title":"Congest Hear Fail"},{"key":"2577_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2015.02.005","volume":"151","author":"M Collino","year":"2015","unstructured":"Collino M, Thiemermann C, Cerami A, Brines M (2015) Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther 151:32\u201340. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.02.005","journal-title":"Pharmacol Ther"},{"key":"2577_CR11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1101\/gad.269894.115","volume":"29","author":"GW Dorn","year":"2015","unstructured":"Dorn GW, Vega RB, Kelly DP (2015) Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev 29:1981\u20131991","journal-title":"Genes Dev"},{"key":"2577_CR12","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/S0140-6736(10)60992-0","volume":"375","author":"P Ghezzi","year":"2010","unstructured":"Ghezzi P, Bernaudin M, Bernaudinb M, Bianchi R, Bianchic R, Blomgren K, Brines M, Campana W, Cavaletti G, Cerami A, Chopp M, Coleman T, Digicaylioglu M, Ehrenreich H, Erbayraktar S, Erbayraktar Z, Gassmann M, Genc S, Gokmen N, Grasso G, Juul S, Lipton SA, Hand CC, Latini R, Lauria G, Leist M, Newton SS, Petit E, Probert L, Sfacteria A, Siren A-L, Talan M, Thiemermann C, Westenbrink D, Yaqoob M, Zhu C (2010) Erythropoietin: not just about erythropoiesis. Lancet (London, England) 375:2142. https:\/\/doi.org\/10.1016\/S0140-6736(10)60992-0","journal-title":"Lancet (London, England)"},{"key":"2577_CR13","doi-asserted-by":"publisher","first-page":"30014","DOI":"10.1074\/jbc.M704817200","volume":"282","author":"C Handschin","year":"2007","unstructured":"Handschin C, Chin S, Li P, Liu F, Maratos-Flier E, LeBrasseur NK, Yan Z, Spiegelman BM (2007) Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1\u03b1 muscle-specific knock-out animals. J Biol Chem 282:30014\u201330021. https:\/\/doi.org\/10.1074\/jbc.M704817200","journal-title":"J Biol Chem"},{"key":"2577_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/BIR-140655","volume":"51","author":"M Hardeman","year":"2014","unstructured":"Hardeman M, Alexy T, Brouwer B, Connes P, Jung F, Kuipers H, Baskurt OK (2014) EPO or PlacEPO? Science versus practical experience: panel discussion on efficacy of erythropoetin in improving performance. Biorheology 51:83\u201390. https:\/\/doi.org\/10.3233\/BIR-140655","journal-title":"Biorheology"},{"key":"2577_CR15","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ejhf.1154","volume":"20","author":"MF Hoes","year":"2018","unstructured":"Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P (2018) Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail 20:910\u2013919. https:\/\/doi.org\/10.1002\/ejhf.1154","journal-title":"Eur J Heart Fail"},{"key":"2577_CR16","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1096\/fj.11-196618","volume":"26","author":"Y Jia","year":"2012","unstructured":"Jia Y, Suzuki N, Yamamoto M, Gassmann M, Noguchi CT (2012) Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage. FASEB J 26:2847\u20132858. https:\/\/doi.org\/10.1096\/fj.11-196618","journal-title":"FASEB J"},{"key":"2577_CR17","doi-asserted-by":"publisher","first-page":"H455","DOI":"10.1152\/ajpheart.00085.2005","volume":"289","author":"JP Konhilas","year":"2005","unstructured":"Konhilas JP, Widegren U, Allen DL, Paul AC, Cleary A, Leinwand LA (2005) Loaded wheel running and muscle adaptation in the mouse. Am J Physiol - Hear Circ Physiol 289:H455-65. https:\/\/doi.org\/10.1152\/ajpheart.00085.2005","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"2577_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.yexcr.2015.07.012","volume":"337","author":"J Kuipers","year":"2015","unstructured":"Kuipers J, de Boer P, Giepmans BNG (2015) Scanning EM of non-heavy metal stained biosamples: large-field of view, high contrast and highly efficient immunolabeling. Exp Cell Res 337:202\u2013207. https:\/\/doi.org\/10.1016\/j.yexcr.2015.07.012","journal-title":"Exp Cell Res"},{"key":"2577_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00418-020-01846-0","volume":"153","author":"J Kuipers","year":"2020","unstructured":"Kuipers J, Giepmans BNG (2020) Neodymium as an alternative contrast for uranium in electron microscopy. Histochem Cell Biol 153:271\u2013277. https:\/\/doi.org\/10.1007\/s00418-020-01846-0","journal-title":"Histochem Cell Biol"},{"key":"2577_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fphys.2013.00176","volume":"4","author":"S Lamon","year":"2013","unstructured":"Lamon S, Russell AP (2013) The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how much do we really know? Front Physiol 4:176. https:\/\/doi.org\/10.3389\/fphys.2013.00176","journal-title":"Front Physiol"},{"key":"2577_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fphys.2016.00292","volume":"7","author":"S Lamon","year":"2016","unstructured":"Lamon S, Zacharewicz E, Arentson-Lantz E, Della GPA, Ghobrial L, Gerlinger-Romero F, Garnham A, Paddon-Jones D, Russell AP (2016) Erythropoietin does not enhance skeletal muscle protein synthesis following exercise in young and older adults. Front Physiol 7:292. https:\/\/doi.org\/10.3389\/fphys.2016.00292","journal-title":"Front Physiol"},{"key":"2577_CR22","doi-asserted-by":"publisher","first-page":"e00256","DOI":"10.1002\/phy2.256","volume":"2","author":"S Lamon","year":"2014","unstructured":"Lamon S, Zacharewicz E, Stephens AN, Russell AP (2014) EPO-receptor is present in mouse C2C12 and human primary skeletal muscle cells but EPO does not influence myogenesis. Physiol Rep 2:e00256. https:\/\/doi.org\/10.1002\/phy2.256","journal-title":"Physiol Rep"},{"key":"2577_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejheart.2007.10.008","volume":"10","author":"E Lipsic","year":"2008","unstructured":"Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH (2008) Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 10:22\u201329. https:\/\/doi.org\/10.1016\/j.ejheart.2007.10.008","journal-title":"Eur J Heart Fail"},{"key":"2577_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10557-017-6742-1","volume":"31","author":"J Lu","year":"2017","unstructured":"Lu J, Dai Q, ming, Ma G shan, Zhu Y hong, Chen B, Li B, Yao Y yu, (2017) Erythropoietin attenuates cardiac dysfunction in rats by inhibiting endoplasmic reticulum stress-induced diabetic cardiomyopathy. Cardiovasc Drugs Ther 31:367\u2013379. https:\/\/doi.org\/10.1007\/s10557-017-6742-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"2577_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1113\/jphysiol.2010.195917","volume":"589","author":"C Lundby","year":"2011","unstructured":"Lundby C, Olsen NV (2011) Effects of recombinant human erythropoietin in normal humans. J Physiol 589:1265\u20131271. https:\/\/doi.org\/10.1113\/jphysiol.2010.195917","journal-title":"J Physiol"},{"key":"2577_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1113\/jphysiol.2006.122689","volume":"578","author":"C Lundby","year":"2007","unstructured":"Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JAL, Robach P (2007) Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 578:309\u2013314. https:\/\/doi.org\/10.1113\/jphysiol.2006.122689","journal-title":"J Physiol"},{"key":"2577_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","volume":"107","author":"DM Mancini","year":"2003","unstructured":"Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107:294\u2013299. https:\/\/doi.org\/10.1161\/01.CIR.0000044914.42696.6A","journal-title":"Circulation"},{"key":"2577_CR28","doi-asserted-by":"publisher","unstructured":"Manzanares G, Brito-Da-Silva G, Gandra PG (2019) Voluntary wheel running: patterns and physiological effects in mice. Brazilian J Med Biol Res 52https:\/\/doi.org\/10.1590\/1414-431X20187830","DOI":"10.1590\/1414-431X20187830"},{"key":"2577_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jsbmb.2012.06.004","volume":"132","author":"LMG Meems","year":"2012","unstructured":"Meems LMG, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Sillj\u00e9 HHW, Ruifrok WPT, de Boer RA (2012) The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol 132:282\u2013289. https:\/\/doi.org\/10.1016\/j.jsbmb.2012.06.004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2577_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1755-8794-5-29","volume":"5","author":"L Mille-Hamard","year":"2012","unstructured":"Mille-Hamard L, Billat VL, Henry E, Bonnamy B, Joly F, Benech P, Barrey E (2012) Skeletal muscle alterations and exercise performance decrease in erythropoietin-deficient mice: a comparative study. BMC Med Genomics 5:29. https:\/\/doi.org\/10.1186\/1755-8794-5-29","journal-title":"BMC Med Genomics"},{"key":"2577_CR31","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/0272-6386(95)90645-2","volume":"26","author":"N Muirhead","year":"1995","unstructured":"Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfrey P (1995) Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 26:S1-24","journal-title":"Am J Kidney Dis"},{"key":"2577_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura M, Sadoshima J (2018) Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 15:387\u2013407. https:\/\/doi.org\/10.1038\/s41569-018-0007-y","journal-title":"Nat Rev Cardiol"},{"key":"2577_CR33","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1161\/01.RES.0000260179.43672.fe","volume":"100","author":"M Nakano","year":"2007","unstructured":"Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H (2007) Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 100:662\u2013669. https:\/\/doi.org\/10.1161\/01.RES.0000260179.43672.fe","journal-title":"Circ Res"},{"key":"2577_CR34","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1017\/S1462399408000860","volume":"10","author":"CT Noguchi","year":"2008","unstructured":"Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y (2008) Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 10:e36. https:\/\/doi.org\/10.1017\/S1462399408000860","journal-title":"Expert Rev Mol Med"},{"key":"2577_CR35","doi-asserted-by":"publisher","first-page":"39754","DOI":"10.1074\/jbc.M004999200","volume":"275","author":"M Ogilvie","year":"2000","unstructured":"Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, Noguchi CT (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275:39754\u201339761. https:\/\/doi.org\/10.1074\/jbc.M004999200","journal-title":"J Biol Chem"},{"key":"2577_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jcm7020024","volume":"7","author":"D Ostrowski","year":"2018","unstructured":"Ostrowski D, Heinrich R (2018) Alternative erythropoietin receptors in the nervous system. J Clin Med 7:24. https:\/\/doi.org\/10.3390\/jcm7020024","journal-title":"J Clin Med"},{"key":"2577_CR37","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/nprot.2008.138","volume":"3","author":"P Pacher","year":"2008","unstructured":"Pacher P, Nagayama T, Mukhopadhyay P, B\u00e1tkai S, Kass DA (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3:1422\u20131434. https:\/\/doi.org\/10.1038\/nprot.2008.138","journal-title":"Nat Protoc"},{"key":"2577_CR38","doi-asserted-by":"publisher","first-page":"43202","DOI":"10.18632\/oncotarget.6439","volume":"6","author":"F Pin","year":"2015","unstructured":"Pin F, Busquets S, Toledo M, Camperi A, Lopez-Soriano FJ, Costelli P, Argil\u00e9s JM, Penna F (2015) Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget 6:43202\u201343215. https:\/\/doi.org\/10.18632\/oncotarget.6439","journal-title":"Oncotarget"},{"key":"2577_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fphys.2012.00050","volume":"3","author":"U Plenge","year":"2012","unstructured":"Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R (2012) Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol 3:50. https:\/\/doi.org\/10.3389\/fphys.2012.00050","journal-title":"Front Physiol"},{"key":"2577_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.freeradbiomed.2016.03.025","volume":"98","author":"R Qaisar","year":"2016","unstructured":"Qaisar R, Bhaskaran S, Van Remmen H (2016) Muscle fiber type diversification during exercise and regeneration. Free Radic Biol Med 98:56\u201367. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2016.03.025","journal-title":"Free Radic Biol Med"},{"key":"2577_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cpmo.21","volume":"7","author":"PM Quiros","year":"2017","unstructured":"Quiros PM, Goyal A, Jha P, Auwerx J (2017) Analysis of mtDNA\/nDNA ratio in mice. Curr Protoc Mouse Biol 7:47\u201354. https:\/\/doi.org\/10.1002\/cpmo.21","journal-title":"Curr Protoc Mouse Biol"},{"key":"2577_CR42","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1530\/EJE-09-0342","volume":"161","author":"H Rundqvist","year":"2009","unstructured":"Rundqvist H, Rullman E, Sundberg CJ, Fischer H, Eisleitner K, St\u00e5hlberg M, Sundblad P, Jansson E, Gustafsson T (2009) Activation of the erythropoietin receptor in human skeletal muscle. Eur J Endocrinol 161:427\u2013434. https:\/\/doi.org\/10.1530\/EJE-09-0342","journal-title":"Eur J Endocrinol"},{"key":"2577_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00424-019-02266-3","volume":"472","author":"DY Seo","year":"2019","unstructured":"Seo DY, Kwak HB, Kim AH, Park SH, Heo JW, Kim HK, Ko JR, Lee SJ, Bang HS, Sim JW, Kim M, Han J (2019) Cardiac adaptation to exercise training in health and disease. Pflugers Arch Eur. J. Physiol 472:155\u2013168","journal-title":"Pflugers Arch Eur. J. Physiol"},{"key":"2577_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu I, Minamino T (2016) Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 97:245\u2013262. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.06.001","journal-title":"J Mol Cell Cardiol"},{"key":"2577_CR45","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/jid.2015.109","volume":"135","author":"E Sokol","year":"2015","unstructured":"Sokol E, Kramer D, Diercks GFH, Kuipers J, Jonkman MF, Pas HH, Giepmans BNG (2015) Large-scale electron microscopy maps of patient skin and mucosa provide insight into pathogenesis of blistering diseases. J Invest Dermatol 135:1763\u20131770. https:\/\/doi.org\/10.1038\/jid.2015.109","journal-title":"J Invest Dermatol"},{"key":"2577_CR46","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3389\/fphys.2019.01534","volume":"10","author":"S Suresh","year":"2020","unstructured":"Suresh S, Rajvanshi PK, Noguchi CT (2020) The Many facets of erythropoietin physiologic and metabolic response. Front Physiol 10:1534","journal-title":"Front Physiol"},{"key":"2577_CR47","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1182\/blood-2002-01-0124","volume":"100","author":"N Suzuki","year":"2002","unstructured":"Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M (2002) Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100:2279\u20132288. https:\/\/doi.org\/10.1182\/blood-2002-01-0124","journal-title":"Blood"},{"key":"2577_CR48","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.cardiores.2006.05.010","volume":"71","author":"H Tada","year":"2006","unstructured":"Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K, Ito K, Karibe A, Shirato K, Minegishi N, Shimokawa H (2006) Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia\/reperfusion. Cardiovasc Res 71:466\u2013477. https:\/\/doi.org\/10.1016\/j.cardiores.2006.05.010","journal-title":"Cardiovasc Res"},{"key":"2577_CR49","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ncomms1526","volume":"2","author":"R Teng","year":"2011","unstructured":"Teng R, Gavrilova O, Suzuki N, Chanturiya T, Schimel D, Hugendubler L, Mammen S, Yver DR, Cushman SW, Mueller E, Yamamoto M, Hsu LL, Noguchi CT (2011) Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun 2:520. https:\/\/doi.org\/10.1038\/ncomms1526","journal-title":"Nat Commun"},{"key":"2577_CR50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.7150\/ijbs.9518","volume":"10","author":"L Wang","year":"2014","unstructured":"Wang L, Di L, Noguchi CT (2014) Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci 10:921\u2013939. https:\/\/doi.org\/10.7150\/ijbs.9518","journal-title":"Int J Biol Sci"},{"key":"2577_CR51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.biocel.2013.03.007","volume":"45","author":"L Wang","year":"2013","unstructured":"Wang L, Jia Y, Rogers H, Suzuki N, Gassmann M, Wang Q, McPherron AC, Kopp JB, Yamamoto M, Noguchi CT (2013) Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1\u03b1 and AMPK activation. Int J Biochem Cell Biol 45:1155\u20131164. https:\/\/doi.org\/10.1016\/j.biocel.2013.03.007","journal-title":"Int J Biochem Cell Biol"},{"key":"2577_CR52","doi-asserted-by":"publisher","first-page":"30157","DOI":"10.1074\/jbc.M112.376640","volume":"287","author":"L Wang","year":"2012","unstructured":"Wang L, Jia Y, Rogers H, Wu YP, Huang S, Noguchi CT (2012) GATA-binding protein 4 (GATA-4) and T-cell acute leukemia 1 (TAL1) regulate myogenic differentiation and erythropoietin response via cross-talk with Sirtuin1 (Sirt1). J Biol Chem 287:30157\u201330169. https:\/\/doi.org\/10.1074\/jbc.M112.376640","journal-title":"J Biol Chem"},{"key":"2577_CR53","doi-asserted-by":"publisher","first-page":"e004129","DOI":"10.1161\/CIRCHEARTFAILURE.117.004129","volume":"10","author":"K Weiss","year":"2017","unstructured":"Weiss K, Sch\u00e4r M, Panjrath GS, Zhang Y, Sharma K, Bottomley PA, Golozar A, Steinberg A, Gerstenblith G, Russell SD, Weiss RG (2017) Fatigability, exercise intolerance, and abnormal skeletal muscle energetics in heart failure. Circ Heart Fail 10:e004129. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004129","journal-title":"Circ Heart Fail"},{"key":"2577_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/HCO.0b013e3282f43025","volume":"23","author":"BD Westenbrink","year":"2008","unstructured":"Westenbrink BD, De Boer RA, Voors AA, Van Gilst WH, Van Veldhuisen DJ (2008) Anemia in chronic heart failure: etiology and treatment options. Curr Opin Cardiol 23:141\u2013147","journal-title":"Curr Opin Cardiol"},{"key":"2577_CR55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10557-008-6094-y","volume":"22","author":"BD Westenbrink","year":"2008","unstructured":"Westenbrink BD, Oeseburg H, Kleijn L, van der Harst P, Belonje AMS, Voors AA, Schoemaker RG, de Boer RA, van Veldhuisen DJ, van Gilst WH (2008) Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc drugs Ther 22:265\u2013274. https:\/\/doi.org\/10.1007\/s10557-008-6094-y","journal-title":"Cardiovasc drugs Ther"},{"key":"2577_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/cvr\/cvq041","volume":"87","author":"BD Westenbrink","year":"2010","unstructured":"Westenbrink BD, Ruifrok W-PT, Voors AA, Tilton RG, van Veldhuisen DJ, Schoemaker RG, van Gilst WH, de Boer RA (2010) Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res 87:30\u201339. https:\/\/doi.org\/10.1093\/cvr\/cvq041","journal-title":"Cardiovasc Res"},{"key":"2577_CR57","doi-asserted-by":"publisher","first-page":"e80815","DOI":"10.1371\/journal.pone.0080815","volume":"8","author":"H Yu","year":"2013","unstructured":"Yu H, Tigchelaar W, Koonen DPY, Patel HH, de Boer RA, van Gilst WH, Westenbrink BD, Sillj\u00e9 HHW (2013) AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes. PLoS ONE 8:e80815. https:\/\/doi.org\/10.1371\/journal.pone.0080815","journal-title":"PLoS ONE"},{"key":"2577_CR58","doi-asserted-by":"publisher","first-page":"21378","DOI":"10.3390\/ijms141121378","volume":"14","author":"H Yu","year":"2013","unstructured":"Yu H, Tigchelaar W, Lu B, van Gilst W, de Boer R, Westenbrink B, Sillj\u00e9 H (2013) AKIP1, a cardiac hypertrophy induced protein that stimulates cardiomyocyte growth via the Akt pathway. Int J Mol Sci 14:21378\u201321393. https:\/\/doi.org\/10.3390\/ijms141121378","journal-title":"Int J Mol Sci"},{"key":"2577_CR59","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.120.007684","author":"SR Yurista","year":"2020","unstructured":"Yurista SR, Matsuura TR, Sillj\u00e9 HHW, Nijholt KT, McDaid KS, Shewale SV, Leone TC, Newman JC, Verdin E, van Veldhuisen DJ, de Boer RA, Kelly DP, Westenbrink BD (2020) Ketone ester treatment improves cardiac function and reduces pathologic remodeling in preclinical models of heart failure. Circ Hear Fail. https:\/\/doi.org\/10.1161\/circheartfailure.120.007684","journal-title":"Circ Hear Fail"},{"key":"2577_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-06999-7","author":"SR Yurista","year":"2020","unstructured":"Yurista SR, Sillj\u00e9 HHW, Nijholt KT, Dokter MM, van Veldhuisen DJ, de Boer RA, Westenbrink BD (2020) Factor Xa inhibition with apixaban does not influence cardiac remodelling in rats with heart failure after myocardial infarction. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-020-06999-7","journal-title":"Cardiovasc Drugs Ther"},{"key":"2577_CR61","doi-asserted-by":"publisher","first-page":"10296","DOI":"10.3390\/ijms150610296","volume":"15","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT (2014) Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci 15:10296\u201310333","journal-title":"Int J Mol Sci"}],"container-title":["Pfl\u00fcgers Archiv - European Journal of Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-021-02577-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00424-021-02577-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-021-02577-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:05:11Z","timestamp":1627027511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00424-021-02577-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1007\/s00424-021-02577-4","relation":{},"ISSN":["0031-6768","1432-2013"],"issn-type":[{"value":"0031-6768","type":"print"},{"value":"1432-2013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was accepted by The Animal Ethical Committee of the University of Groningen (DEC4585\/IvD 1583\u201302-011, 1583\u201302-014). In addition, all animal experiments followed the protocols from Directive 2010\/63\/EU of the European Parliament.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The UMCG, which employs several of the authors, has received research grants and\/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk and Roche. Dr. de Boer received speaker fees from Abbott, AstraZeneca, Novartis and Roche. The other authors do not have any conflict of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}